Kalina Scott appointed new CFO of Polyphor

Kalina Scott will join Polyphor, a clinical stage, privately held Swiss specialty pharma company, focused on the development of macrocycle drugs that address antibiotic resistance and severe respiratory diseases, as Chief Financial Officer.

She brings more than 20 years of experience in the fields of mergers and acquisitions, capital markets and private placements in particular in the healthcare field, most recently as Managing Director, Corporate Finance with Bank am Bellevue in Zurich.

Scott started her career at UBS focusing on structured finance and credit risk management, followed by leading roles in UBS's investment banking in Zurich and London, covering leveraged finance as well as mergers and acquisitions and in KPMG s Corporate Finance, where she built an IPO advisory unit.

During her career, she successfully executed corporate finance transactions for more than 20 companies companies including the IPOs of Molecular Partners, Cassiopea and more recently Galenica Santé, as well as strategic transactions for Berna Biotech, Sulzer Medica, Mathys Medical and the Hirslanden group.

Kalina succeeds Alain Schaffter, who will leave Polyphor to take on a new challenge.

Giacomo Di Nepi, Polyphor's CEO, said:

“Kalina extensive experience in the finance area, combined with her transaction-based expertise in healthcare will help to grow Polyphor and support our corporate strategy and transformation.”

Scott, a Swiss and Bulgarian citizen, studied Business and Economics at the University of Leipzig, Germany and is a Bachelor of Business Administration at the Sofia University in Bulgaria.

You may also like